drugset / Trial / NCT00496834

LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

NCT00496834

Phase 4 Completed 201 enrolled Organon and Co
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the essential hypertension.

Timeline

Start
2008-02-01
Primary completion
2009-09-01
Completion
2009-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carvedilol Other / unclassified 12.5 mg
Comparator Carvedilol Other / unclassified 25 mg
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Hydrochlorothiazide Unknown 25 mg
Subject Losartan Other / unclassified 50 mg
Subject Losartan Other / unclassified 100 mg

Indications